Cabozantanibisananticancerchemotherapeuticcompoundthathasbeenapprovedtotreatmedullarythyroidcancerandisinclinicaltrialsasatreatmentforothertypesofsolidtumors.CabozantanibexertsitsanticanceractivitythroughinhibitionofMet,RET,andVEGFR2,increasingapoptosisandinhibitingcellgrowthandosteoclastproliferationinvitroandinvivo.
| CasNo. | 849217-68-1 |
|---|---|
| Purity | ≥98% |
| Formula | C28H24FN3O5 |
| FormulaWt. | 501.51 |
| ChemicalName | N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| IUPACName | 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N"-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| Synonym | XL-184,BMS-907351 |
| Solubility | SolubleinDMSO(≥117mg/mL),insolubleinwater(≤1mg/mL). |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| MSDS | C0006MSDSPDF |
|---|---|
| InfoSheet | C0006InfoSheetPDF |
DaiJ,ZhangH,KaratsinidesA,etal.Cabozantinibinhibitsprostatecancergrowthandpreventstumor-inducedbonelesions.ClinCancerRes.2013Oct4.[Epubaheadofprint].PMID:24097861.
EliseiR,SchlumbergerMJ,MüllerSP,etal.Cabozantinibinprogressivemedullarythyroidcancer.JClinOncol.2013Oct10;31(29):3639-46.PMID:24002501.
BentzienF,ZuzowM,HealdN,etal.InVitroandInVivoActivityofCabozantinib(XL184),anInhibitorofRET,MET,andVEGFR2,inaModelofMedullaryThyroidCancer.Thyroid.2013Sep17.[Epubaheadofprint].PMID:23705946.
NavisAC,BourgonjeA,WesselingP,etal.Effectsofdualtargetingoftumorcellsandstromainhumanglioblastomaxenograftswithatyrosinekinaseinhibitoragainstc-METandVEGFR2.PLoSOne.2013;8(3):e58262.PMID:23484006.
